OMACETAXINE MEPESUCCINATE SHOWS ACTIVITY IN ...

Hasil Telusur

    OMACETAXINE MEPESUCCINATE SHOWS ACTIVITY IN ...
    ‎
    MarketWatch (press release) - 1 Jun 2012
    Pooled Safety Analysis of Omacetaxine Mepesuccinate in Patients With Chronic Myeloid Leukemia (CML) Resistant to Tyrosine-Kinase Inhibitors (TKIs).
    Kinase Inhibitor Trials Show Melanoma Benefits
    ‎
    Drug Discovery & Development - 7 Jun 2012
    GlaxoSmithKline has release data from two Phase 3 studies evaluating single-agent therapy with dabrafenib and trametinib in patients with metastatic ...
    Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial ...
    ‎
    MarketWatch (press release) - 13 Jun 2012
    Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial Initiation of a FGFR Kinase Inhibitor. DUBLIN, Calif., Jun 13, 2012 (GlobeNewswire via ...
    Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial ...
    ‎
    GlobeNewsWire (press release) - 13 Jun 2012
    Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial Initiation of a FGFR Kinase Inhibitor. DUBLIN, Calif., June 13, 2012 (GLOBE NEWSWIRE) ...
    Astex lands £3.5m milestone as cancer drug enters Phase I‎ Cabume - Cambridge technology news
    Seluruh 19 artikel berita »
    Cell Therapeutics Completes Acquisition of Pacritinib a Highly ...
    ‎
    MarketWatch (press release) - 3 Jun 2012
    About PacritinibPacritinib is an oral, once a day, tyrosine kinase inhibitor (TKI) with dual activity against JAK2 and FMS-like tyrosine kinase 3 ("FLT3"). Mutations ...
    Cell Therapeutics Says It Completes Acquisition Of Pacritinib - Quick ...‎ NASDAQ
    Seluruh 16 artikel berita »
    Inhibition of Src kinase activity attenuates amyloid associated ...
    ‎
    7thSpace Interactive (press release) - 6 Jun 2012
    Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease - up-to-the-minute news and headlines.
    Patients with NK/T-cell lymphomas might benefit from treatment with ...
    ‎
    News-Medical.net - 15 Jun 2012
    Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a study published in Cancer Discovery, a journal of the ...
    MethylGene Presents MGCD265 Data at the 2012 American Society ...
    ‎
    MarketWatch (press release) - 4 Jun 2012
    The poster, entitled "MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation Phase I study" (Abstract #3039) ...
    Xcovery Presents Phase 1 Clinical Results at ASCO Annual Meeting‎ Marketwire (press release)
    MethylGene (MYG-TO, MYLGF-OTC): Initiating with an Outperform‎ Zacks.com
    Seluruh 10 artikel berita »
    Constitutively active c-Met kinase in PC-3 cells is autocrine ...
    ‎
    7thSpace Interactive (press release) - 28 Mei 2012
    In the current study we examined the response of PC-3 cells to an anti-HGF neutralizing antibody or a small molecule Met kinase inhibitor (BMS-777607).
    Xcovery Presents Phase 1 Clinical Results at ASCO Annual Meeting
    ‎
    MarketWatch (press release) - 4 Jun 2012
    VEGFR tyrosine kinase inhibitors have characteristically demonstrated benefit in a variety of cancers, though it has been well documented that the dosage and ...